Global Overactive Bladder Treatment Market: Drivers, Restraints, Opportuniities, and Challenges

on
The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence. The global market is projected to be valued at USD 3.63 Billion in 2017 and is expected to grow at a CAGR of 2.9% during the forecast period to reach to USD 4.19 Billion by 2022. Base year considered for the report is 2016. The development of innovative intravesical therapies, aggressive marketing by pharma companies, and favorable demographics are the key factors driving the growth of the market.
Key Growth Drivers : 
1 Development of Innovative Intravesical Therapies
2 Aggressive Marketing By Pharma Companies
3 Aging Population and Rising Incidence of Diseases Characterized By OAB
Geographically, the global market is segmented into the U.S., Europe, Asia-Pacific, and the Rest of the World. In 2016, the U.S. dominated the market and this is primarily attributed to its well-established healthcare industry with favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. The Rest of Asia-Pacific region is expected to witness the highest CAGR during the forecast period owing to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness on overactive bladder.
In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the global market. Some of the other players competing in market are Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International Plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

Comments

Post a Comment